ストックスクリーナーアプリを入手
77.13
4.09%
-3.29
アフターアワーズ：
77.50
0.37
+0.48%
前日終値:
$80.42
開ける：
$80.32
24時間の取引高:
1.58M
Relative Volume:
0.62
時価総額：
$10.47B
収益：
$105.82M
当期純損益:
$-829.61M
株価収益率:
-11.27
EPS:
-6.8429
ネットキャッシュフロー:
$-548.92M
1週間 パフォーマンス:
-4.47%
1か月 パフォーマンス:
-9.46%
6か月 パフォーマンス:
+22.06%
1年 パフォーマンス:
+104.91%
1日の値動き範囲:
$76.96
$80.81
1週間の範囲:
$76.96
$82.41
52週間の値動き範囲:
$32.89
$88.31
Cytokinetics Inc Stock (CYTK) Company Profile
名前
Cytokinetics Inc
セクター
電話
(650) 624-3000
住所
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
77.13 | 10.95B | 105.82M | -829.61M | -548.92M | -6.8429 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-10 | 開始されました | Wells Fargo | Overweight |
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2025-12-18 | アップグレード | Goldman | Neutral → Buy |
| 2025-07-30 | 再開されました | Raymond James | Mkt Perform |
| 2025-04-24 | 開始されました | Barclays | Overweight |
| 2025-02-07 | 開始されました | Citigroup | Buy |
| 2025-01-22 | 開始されました | Stifel | Buy |
| 2024-11-08 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-08-13 | ダウングレード | Goldman | Buy → Neutral |
| 2024-01-24 | ダウングレード | UBS | Buy → Neutral |
| 2024-01-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | 開始されました | Goldman | Buy |
| 2023-11-07 | 開始されました | B. Riley Securities | Buy |
| 2023-08-15 | 開始されました | SVB Securities | Outperform |
| 2023-02-17 | 開始されました | BofA Securities | Neutral |
| 2022-12-23 | 繰り返されました | Needham | Buy |
| 2022-12-20 | 開始されました | Truist | Buy |
| 2022-10-11 | 開始されました | UBS | Buy |
| 2022-01-28 | 開始されました | Goldman | Buy |
| 2021-12-22 | 開始されました | Oppenheimer | Outperform |
| 2021-12-10 | 開始されました | JP Morgan | Overweight |
| 2021-10-07 | 開始されました | Jefferies | Buy |
| 2021-03-12 | 開始されました | Wolfe Research | Outperform |
| 2021-02-18 | 開始されました | Barclays | Overweight |
| 2021-01-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-29 | 開始されました | Goldman | Neutral |
| 2020-07-10 | 開始されました | Raymond James | Strong Buy |
| 2020-05-05 | 開始されました | Mizuho | Buy |
| 2020-04-09 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-09-10 | 再開されました | Morgan Stanley | Equal-Weight |
| 2017-11-22 | 繰り返されました | Morgan Stanley | Overweight |
| 2017-11-22 | ダウングレード | Needham | Strong Buy → Buy |
| 2017-11-21 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-07-31 | 開始されました | Morgan Stanley | Overweight |
| 2017-03-08 | 開始されました | Rodman & Renshaw | Buy |
| 2017-02-06 | アップグレード | Needham | Buy → Strong Buy |
| 2016-12-16 | 開始されました | Cantor Fitzgerald | Overweight |
| 2016-07-28 | 繰り返されました | Needham | Buy |
| 2015-11-10 | 繰り返されました | FBR Capital | Outperform |
| 2015-11-09 | 繰り返されました | ROTH Capital | Buy |
| 2015-07-24 | 繰り返されました | MLV & Co | Buy |
| 2014-12-31 | 繰り返されました | ROTH Capital | Buy |
| 2014-11-04 | アップグレード | MLV & Co | Hold → Buy |
| 2014-04-28 | 繰り返されました | Needham | Buy |
すべてを表示
Cytokinetics Inc (CYTK) 最新ニュース
CYTK4910847 Bond Profile — Key Metrics - TradingView
Form 4 Cytokinetics Inc For: 27 July By Investing.com - Investing.com Canada
Cytokinetics (NASDAQ: CYTK) CEO sells 7,500 shares after option exercise - Stock Titan
Cytokinetics president & CEO Robert Blum sells $606,525 in stock By Investing.com - Investing.com Canada
Cytokinetics president & CEO Robert Blum sells $606,525 in stock - Investing.com
Cytokinetics Insider Sold Shares Worth $606,525, According to a Recent SEC Filing - Yahoo Finance
Cytokinetics Inc (CYTK) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cytokinetics Inc (CYTK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cytokinetics Inc (CYTK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cytokinetics Inc (CYTK) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CYTK|Cytokinetics Inc|Price:80.740|Chg%:-1.180 - TradingKey
Cytokinetics Inc (CYTK) Balance Sheet - TradingKey
Cytokinetics, Incorporated Revenue Breakdown – BX:KK3A - TradingView
Cytokinetics, Incorporated Revenue Breakdown – FWB:KK3A - TradingView
Cytokinetics, Incorporated Revenue Breakdown – LS:A1W1KK - TradingView
Cytokinetics, Incorporated (CYTK) Stock Forecasts - Yahoo! Finance Canada
Cytokinetics, Incorporated (CYTK) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cytokinetics, Incorporated (CYTK) stock price, news, quote and history - Yahoo Finance UK
Cytokinetics EVP Fady Malik sells $282,065 in company stock By Investing.com - Investing.com Nigeria
Form 4 Cytokinetics Inc For: 24 July By Investing.com - Investing.com Nigeria
Cytokinetics EVP Fady Malik sells $282,065 in company stock - Investing.com
Cytokinetics Inc (CYTK) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Insider Sell Alert: Fady Malik Sells 3,500 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics Insider Sold Shares Worth $282,065, According to a Recent SEC Filing - marketscreener.com
Cytokinetics to Announce Second Quarter Results on August 6, 2026 - The Manila Times
Cytokinetics Will Share Q2 Results Aug. 6, Then Host Live Call - Stock Titan
CYTK stock holds recent gains as Cytokinetics prepares next heart failure data readout - AD HOC NEWS
Cytokinetics Inc (CYTK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cytokinetics, Incorporated (CYTK) Options Chain - Yahoo! Finance Canada
Cytokinetics: Label Expansion Can Turn MYQORZO Into An HCM Franchise (NASDAQ:CYTK) - Seeking Alpha
Cytokinetics' Myqorzo: The Challenger Drug Poised to Reshape a Multi-Billion Dollar Heart Market - Kavout | AI
Cytokinetics CEO on the launch of its first commercial drug - Yahoo Finance
Cytokinetics stock edges higher as cardiovascular pipeline and cash position underpin outlook - Ad-hoc-news.de
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Citi Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $99 - Moomoo
Form 4 Cytokinetics Inc For: 16 July By Investing.com - Investing.com Nigeria
Cytokinetics (CYTK) director Nancy Wysenski granted 75 fully vested shares - Stock Titan
Director stock grant at Cytokinetics (CYTK) highlights equity retainer - Stock Titan
Cytokinetics (CYTK) awards 151-share fully vested grant to director - Stock Titan
Cytokinetics Inc (CYTK) director granted 272 fully vested shares - Stock Titan
Cytokinetics (NASDAQ: CYTK) director receives 151-share equity retainer grant - Stock Titan
Cytokinetics (NASDAQ: CYTK) awards director 151 fully vested shares - Stock Titan
All You Need to Know About Cytokinetics (CYTK) Rating Upgrade to Buy - Yahoo Finance Singapore
Wall Street Analysts Think Cytokinetics (CYTK) Could Surge 30.54%: Read This Before Placing a Bet - Yahoo Finance
Braveheart files for IPO to fund Phase 3 of Hengrui’s Cytokinetics rival - Endpoints News
US23282WAC4 Bond Profile — Key Metrics - TradingView
Cytokinetics president & CEO Robert Blum sells $615,149 of stock - Investing.com UK
FMR LLC Reduces Stake in Cytokinetics Inc: A Detailed Analysis - GuruFocus
What This Cytokinetics Insider Sale Might Mean With the Stock Up 110% - The Motley Fool
Cytokinetics president & CEO Robert Blum sells $615,149 of stock By Investing.com - Investing.com South Africa
What This Cytokinetics Insider Sale Might Mean With the Stock Up 110% - The Motley Fool
Cytokinetics Inc (CYTK) 財務データ
収益
当期純利益
現金流量
EPS
Cytokinetics Inc (CYTK) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Callos Andrew | EVP, Chief Commercial Officer |
Jul 30 '26 |
Sale |
79.88 |
14,000 |
1,118,320 |
58,555 |
2.44%
0.02%
大文字化:
|
ボリューム (24 時間):